Expression of RSUME is Associated With Poor Prognosis in Clear Cell Renal Carcinoma: Involvement of ROS Related Metabolism - Beyond the Abstract

In @ArztLab, an in silico and in vitro approach was used to examine RSUME/RWDD3 gene in clear cell renal cell carcinoma (ccRCC). The research analyzed the expression of the RSUME/RWDD3 gene in ccRCC patients using RNA-seq and microarray-based methods.

The findings demonstrated that RSUME expression was significantly elevated in ccRCC tumors compared to normal tissue and was associated with unfavorable clinical outcomes, including overall and disease-specific survival, as well as increased morbidity characteristics.

Furthermore, the investigation revealed a correlation between RSUME expression and higher serum calcium levels, a recognized prognostic indicator of cancer clinical outcomes.

In addition, RSUME was linked to the reprogramming of glycerophospholipid and ROS-related metabolism.

In conclusion, the research suggests that RSUME/RWDD3 may serve as a promising independent prognostic biomarker and therapeutic target in ccRCC and should thus undergo further validation.

Written by: David Gonilski-Pacin, Nicolas Ciancio Del Giudice, Belen Elguero, Eduardo Arzt

Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina., Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina; Departamento de Fisiología y Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.

Read the Abstract